ReportLinker
The Global Type 2 Diabetes Drugs Market size was estimated at USD 60. 82 billion in 2021 and expected to reach USD 65. 75 billion in 2022, and is projected to grow at a CAGR 8. 38% to reach USD 98.
New York, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Type 2 Diabetes Drugs Market Research Report by Drug, Application, Distribution, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p06342114/?utm_source=GNW 62 billion by 2027.
Market Statistics:The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:This research report categorizes the Type 2 Diabetes Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Drug, the market was studied across Injectables and Oral. The Injectables is further studied across Aspart, Exenatide, Glargine, Insulin, Leraglutide, and Pramlintide. The Oral is further studied across Alpha-Glucosidase Inhibitors, Biguanides, Dipeptidyl Peptidase-4 Inhibitors, Glucagon-Like Peptide, Receptor Agonists, Secretagogues, Sodium Glucose Cotransport 2 Inhibitors, Sulfonylureas, and Thiazolidinediones.
Based on Application, the market was studied across Cardiovascular Safety, Glycemic Control, and Hypoglycemia Avoidance.
Based on Distribution, the market was studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Type 2 Diabetes Drugs market considering the current update on the conflict and its global response.
Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Type 2 Diabetes Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitors strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Type 2 Diabetes Drugs Market, including Abbott Laboratories, Amgen Inc., AstraZeneca Plc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Chugai Pharmaceutical Co., Daiichi Sankyo Co. Ltd, Eli Lilly and Co., GlaxoSmithKline Plc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Novo Nordisk AS, Peptron, Pfizer Inc., Sanofi Aventis A/S, Sanofi SA, Sun Pharmaceutical Industries Limited, and Takeda Pharmaceutical Co. Ltd.
The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:1. What is the market size and forecast of the Global Type 2 Diabetes Drugs Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Type 2 Diabetes Drugs Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Type 2 Diabetes Drugs Market?4. What is the competitive strategic window for opportunities in the Global Type 2 Diabetes Drugs Market?5. What are the technology trends and regulatory frameworks in the Global Type 2 Diabetes Drugs Market?6. What is the market share of the leading vendors in the Global Type 2 Diabetes Drugs Market?7. What modes and strategic moves are considered suitable for entering the Global Type 2 Diabetes Drugs Market?Read the full report: https://www.reportlinker.com/p06342114/?utm_source=GNW
About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Story continues
- This 'itchy' symptom is an early sign of diabetes that people often miss; know more about it - The Times of India - February 7th, 2025
- Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024 - ABC News - February 7th, 2025
- Incidence of type 2 diabetes and metabolic syndrome by Occupation 10-Year follow-up of the Gutenberg Health Study - BMC Public Health - February 7th, 2025
- Abbotts Above the Bias Film Reveals Misconceptions Can Impact Diabetes Care - MultiVu - February 7th, 2025
- Q&A: Diabetes care for the aging population in the digital age - Medical Xpress - February 7th, 2025
- The relationship between oxLDL, sLOX-1, PCSK9 and carotid intima-media thickness in patients with prediabetes and type 2 diabetes - Nature.com - February 7th, 2025
- Nanoparticle Therapy has Potential to Reprogram the Immune System in Type 1 Diabetes - Managed Healthcare Executive - February 7th, 2025
- Muscle quality index is correlated with insulin resistance and type 2 diabetes mellitus: a cross-sectional population-based study - BMC Public Health - February 7th, 2025
- Assessing type-2 diabetes risk based on the Indian diabetes risk score among adults aged 45 and above in India - Nature.com - February 7th, 2025
- Single-cell atlas of human pancreatic islet and acinar endothelial cells in health and diabetes - Nature.com - February 7th, 2025
- Sugary Drinks Fuel Millions of Diabetes and CVD Cases - Medscape - February 7th, 2025
- 1 in 5 UK adults estimated to have diabetes in new record high - Euronews - February 7th, 2025
- New, increasingly widely used diabetes medication may have additional health benefits for older adults - Medical Xpress - February 7th, 2025
- Patients using diabetes apps can miss critical alerts. Heres how to make sure youre getting them - Canon City Daily Record - February 7th, 2025
- Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024 - News-Press Now - February 7th, 2025
- Does wearing a continuous glucose monitor help people without diabetes? We asked experts. - Popular Science - February 7th, 2025
- What is prediabetes and what can you do to stop it? - The Independent - February 7th, 2025
- Diabetes symptoms: 6 high blood sugar warning signs that show on hand and feet - India.com - February 7th, 2025
- The #1 Habit for Better Heart Health If You Have Diabetes, According to Experts - EatingWell - February 7th, 2025
- 'Fix Broken Food System!' Government Urged as Study Says 1 in 5 Brits Affected by Diabetes - Men's Health UK - February 7th, 2025
- World Diabetes Day 2024 - World Health Organization (WHO) - December 6th, 2024
- The WHO Global Diabetes Compact - December 6th, 2024
- Diabetes - World Health Organization (WHO) - December 6th, 2024
- Kumamoto University researchers discover groundbreaking antidiabetic compound - EurekAlert - December 6th, 2024
- Med's David Kaelber comments on GLP-1 agonists, which provide benefits like managing diabetes and weight loss - The Daily | Case Western Reserve... - December 6th, 2024
- Jordan Chiles Is On a Mission To Raise Awareness for Early Type 1 Diabetes Screening - Verywell Health - December 6th, 2024
- There's A Tasty Food That May Reduce Your Risk Of Developing Type 2 Diabetes, Study Shows - HuffPost - December 6th, 2024
- Empagliflozin Linked to Lower Risk of Diabetic Retinopathy Progression - Medpage Today - December 6th, 2024
- GLP-1 Medications Associated with Reduced Likelihood of Dementia Compared to Other Diabetic Meds - Epic Research - December 6th, 2024
- Sanders Slams Greed That Led to Surge in Obesity, Diabetes in US - The Well News - December 6th, 2024
- Eli Lilly to Expand Facility to Meet Demand for Diabetes, Obesity Treatments - The Wall Street Journal - December 6th, 2024
- New Study Teases Out Chocolate and Diabetes Connection - Medpage Today - December 6th, 2024
- Diabetes tool turned wellness trend: Is a glucose monitor right for you? - KARE11.com - December 6th, 2024
- Reporter doesnt have diabetes but wore a glucose monitor anyway. Here's what she learned - CNN - December 6th, 2024
- Lilly's Zepbound (tirzepatide) superior to Wegovy (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% - Investors |... - December 6th, 2024
- I dont have diabetes, but I wore a glucose monitor for six weeks. Heres what I learned about food (and anxiety) - CNN - December 6th, 2024
- Higher niacin levels linked to lower cardiovascular risk, but not in those with diabetes - Healio - December 6th, 2024
- This Type Of Chocolate Could Reduce Type 2 Diabetes Risk By 21% - NDTV - December 6th, 2024
- New Study Links Safer BPA Alternatives to Obesity, Diabetes, and Hormone Disruption - SciTechDaily - December 6th, 2024
- Turns Out Dark Chocolate Has a Health Benefit That's Shockingly GreatAnd Totally Unexpected - Well+Good - December 6th, 2024
- Global report on diabetes - World Health Organization (WHO) - October 22nd, 2024
- Ultra-processed food may be particularly harmful for people with diabetes, scientists warn - The Independent - October 22nd, 2024
- New drugs may be able to treat multiple problems beyond diabetes - The Straits Times - October 22nd, 2024
- Best Fruits for Diabetes (and What To Avoid) - Health Essentials - October 22nd, 2024
- Cutting Sugar May Reduce Your Diabetes, Stroke, and Depression Risk - Healthline - October 22nd, 2024
- Can Diabetes Care Teams Improve Patient Outcomes and Value? - Medscape - October 22nd, 2024
- Oral Semaglutide Reduces MACE Risk in People With Type 2 Diabetes and CVD - MD Magazine - October 22nd, 2024
- High expression of CNOT6L contributes to the negative development of type 2 diabetes - Nature.com - October 22nd, 2024
- Recent Advances and Therapeutic Benefits of Glucagon-Like Peptide-1 (GLP-1) Agonists in the Management of Type 2 Diabetes and Associated Metabolic... - October 22nd, 2024
- Dental teams could detect undiagnosed diabetes in more than one million people with new care pathway - Nature.com - October 22nd, 2024
- Groundbreaking Innovations in Diabetes Care: Highlights from the 2024 Diabetes Technology Meeting - Beyond Type 1 - October 22nd, 2024
- COVID-19 linked to type 2 diabetes onset in children - Medical Xpress - October 22nd, 2024
- The effect of adding pancreatin to standard otilinium bromide and simethicone treatment in type 2 diabetes mellitus patients with irritable bowel... - October 22nd, 2024
- Does microdosing Ozempic work? What experts are saying about the diabetes drug also used for weight loss - Medical Xpress - October 22nd, 2024
- The Link between GLP-1 Drugs and Diabetic Retinopathy Is Not So Clear | AAO 2024 - Managed Healthcare Executive - October 22nd, 2024
- The overexpression of human amylin in pancreatic cells facilitate the appearance of amylin aggregates in the kidney contributing to diabetic... - October 22nd, 2024
- RNAO releases updated guidelines for diabetic foot ulcer care - Benefits and Pensions Monitor - October 22nd, 2024
- COVID-19 raises the risk of type 2 diabetes in children, study reveals - News-Medical.Net - October 22nd, 2024
- Semaglutide: What impact does it really have on heart health? - Medical News Today - October 22nd, 2024
- Glucose monitors for diabetes have finally been funded but a chronic workforce shortage will limit the benefits - The Conversation - October 22nd, 2024
- Early vs Late Fast Window: Is One More Effective? - Medscape - September 13th, 2024
- Breakthrough T1D Walk to Cure Type 1 Diabetes - KATU - September 13th, 2024
- Foods That May Increase Kids' Risk of Type 1 Diabetes Revealed - Newsweek - September 13th, 2024
- Beds and Herts patients to be re-tested in diabetes results error - BBC.com - September 13th, 2024
- This common habit increases your diabetes risk by 50%; Heres how to fix it - The Economic Times - September 13th, 2024
- Elevated risk of pre-diabetes and diabetes in people with past history of COVID-19 in northeastern Nigeria - BMC Public Health - September 13th, 2024
- Study links bananas, oats and yoghurt to greater diabetes risk in susceptible children - The Guardian - September 13th, 2024
- Could the Norton research teams studying diabetes and Alzheimer's come up with a cure? - Courier Journal - September 13th, 2024
- Weight loss, better beta-cell function tied to long-term glycemic control with tirzepatide - Healio - September 13th, 2024
- Study finds weekly insulin injections as effective for diabetes as daily shots - UPI News - September 13th, 2024
- Ozempic, Wegovy, Rybelsus: Are we losing sight of overall health? Heres what the science says - The Conversation - September 13th, 2024
- With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes - PR Newswire - September 13th, 2024
- Dining with Diabetes workshops offered - The Courier-Express - September 13th, 2024
- Researchers uncover connection between two common diabetes drugs with implications for foot ulcer healing - News-Medical.Net - September 13th, 2024
- The menopause can increase your likelihood of developing heart disease, type 2 diabetes and hypertension but exercise can help lower risk - The... - September 13th, 2024
- Artificial pancreas shows promise in people with type 1 diabetes on kidney dialysis - MSN - September 13th, 2024
- How an Indian executive battled flesh-eating disease and diabetes, and won - South China Morning Post - September 13th, 2024
- India brings early Diabetic Retinopathy detection to the last mile with Artificial Intelligence - PR Newswire - September 13th, 2024
- Why this diabetes drug may be the answer to NASA search for radiation protection - Texas Public Radio - September 13th, 2024
- The National Association of Chain Drug Stores and the American Diabetes Association Promote Nutrition Security and its Role in Preventing and Managing... - September 13th, 2024